Brief: Neovacs syas phase IIb trial Ifnalpha Kinoid in Lupus gets positive IDSMB review

Neovacs SA

11/07/2017 06:30

July 11 (Reuters) - NEOVACS SA  ALNEV.PA  
    * REG-NEOVACS ANNOUNCES POSITIVE IDSMB REVIEW FOR PHASE IIB 
CLINICAL TRIAL OF IFNALPHA KINOID IN LUPUS 
    * THIRD IDSMB DATA REVIEW OF ONGOING PHASE IIB CLINICAL 
TRIAL 
    * "ALL PATIENTS ARE NOW FOLLOWED DURING 9 MONTHS, AND OUR 
GOAL IS TO REPORT DATA IN Q2 2018." 
 
Source text for Eikon:  ID:nGNE3RzMLh  
Further company coverage:  ALNEV.PA  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))